£495.00

The 2023-2028 Outlook for Bioengineered Monoclonal Antibodies Protein Drugs in Japan

Subjects

Price data last checked 154 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 24 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 577 days • 577 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 577 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (577 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 577 days

Description

This study covers the latent demand outlook for bioengineered monoclonal antibodies protein drugs across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for bioengineered monoclonal antibodies protein drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of bioengineered monoclonal antibodies protein drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott India, Amgen, Bayer, Biocon, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck & Company, Novartis International, Panacea Biotec, and ProBioGen. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BP9W1RRN
Category: Books > Subjects
Domain: Amazon UK
Release Date: 28 November 2022
Listed Since: 07 December 2022

The 2023-2028 Outlook for Bioengineered Monoclonal Antibodies Protein Drugs in Japan

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2026-2031 World Outlook for High Potency APIs (HPAPIs)

The 2023-2028 Outlook for Drug Delivery Products for US Zip Codes

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs for US Zip Codes

The 2023 Report on Pharma Contract Sales: World Market Segmentation by City

The 2023-2028 World Outlook for Pain-Relieving Lidocaine Patches

The 2025-2030 World Outlook for Peripheral Neuropathy Treatments

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in China

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in Japan

The 2023-2028 Outlook for Prefilled Syringes and Cartridges for US Zip Codes

The 2023-2028 Outlook for Polycarbonate Vial Adaptors for Reconstitution Drugs in the United States

The 2023-2028 Outlook for Anti-Arthritic Drugs in Japan

The 2023 Report on E-Pharma: World Market Segmentation by City

Pharmaceutical Science to Improve the Human Condition: Prix Galien 2011, Volume 1263 (Annals of the New York Academy of Sciences)

The 2023 Report on Transdermal Patches: World Market Segmentation by City

Mastering Strategic Marketing For Specialty Pharmaceuticals: A Hands-on Guide

The 2023 Report on DNA Testing: World Market Segmentation by City

Dorosz guide pratique des medicaments 2023, 42e ed

Biologics and Biosimilars: Drug Discovery and Clinical Applications

The 2023-2028 World Outlook for Succinic Acids

Pharmaceutical Science to Improve the Human Condition: Prix Galien 2010, Volume 1222: 77 (Annals of the New York Academy of Sciences)

Biosimilars and Interchangeable Biologics: Strategic Elements

Development of Biopharmaceutical Drug-Device Products: 35 (AAPS Advances in the Pharmaceutical Sciences Series, 35)

Development of Biopharmaceutical Drug-Device Products: 35 (AAPS Advances in the Pharmaceutical Sciences Series, 35)

The 2023-2028 World Outlook for Electronic Trial Master File (eTMF) Systems